Beringea est. 1988, transatlantic VC with offices Detroit/London. AUM £715m+ (UK ProVen VCTs £300m+, US funds separate). 280+ portfolio investments, 60 exits incl. Sharecare, InTouch, Blis, Monica Vinader (Bridgepoint exit 13yr hold). Recent investments: Limitless Travel (£6.5m Series A 2025), AccessPay (follow-on £9m 2019 lead), Iceberg Data Lab (£10m Series A 2024), Gorilla (€23m 2024), MOTH (£4.6m 2024). Operates as SEC-registered advisor (US).
Investment Focus
Investment Thesis
Growth equity focus: £5-25m checks in Series A+ profitable/near-profitable tech, SaaS, fintech, healthcare, consumer. Strong UK-US cross-border expertise. Patient capital model, 35+ yr track record. Sector agnostic but avoids early-stage pre-revenue. Portfolio avg c.£8-12m check. Partners include Charles Rothstein, Stuart Veale. Co-manages ProVen VCTs (£300m+ AUM UK), Michigan Growth Capital Funds (US $2-10m focus). Team: 21 staff, 9 partners.
Interested in connecting?
Visit their website or reach out directly.